Summary
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded 01/30/2014 and is headquartered in Brooklyn, NY.
Presentations
Current Coverage
- FirstWave Bio- Coverage Termination 03.30.23
- AzurRX Allocation and Target Decreases 08.25.21
- AzuRX BioPharma Update 08.26.20.rev
- MS1819_Combination_Therapy_Interim_Data_Presentation_Final_2020.08.11
- AzuRX BioPharma Allocation Upgrade 04.04.20
-
AzuRX BioPharma General Update 03.02.20.rev
- Allocation Increase- 9/25/2019
- Allocation Increase- 7/11/2019
- Allocation Increase- 2/26/2019
- Research Notes- 10/16/2018
- Research Notes- 9/24/2018
- Allocation Increase- 5/2/2018
- 2017 Fiscal Earnings Update- 4/16/2017
- Initiating Coverage- 2/7/2018